Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients

Citation
Yh. Cao et al., Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients, INT J MOL M, 5(5), 2000, pp. 547-551
Citations number
27
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Medical Research General Topics
Journal title
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
ISSN journal
1107-3756 → ACNP
Volume
5
Issue
5
Year of publication
2000
Pages
547 - 551
Database
ISI
SICI code
1107-3756(200005)5:5<547:ELOUAA>2.0.ZU;2-T
Abstract
Previously, a specific angiogenesis inhibitor, angiostatin, discovered in u rine and serum of tumor-bearing mice, was reported to potently block tumor growth and metastasis in animal models. Detection of angiostatin and its pr ecursor proteins in urine from cancer patients has not been reported. Now, we report the development of an antibody-based analysis system that allows us to detect angiostatin and plasminogen/plasmin (Pgn/plasmin) in the urine of cancer patients. The detection system is a combination of a novel lysin e-ELISA assay and Western immunoblot analysis using a specific antibody to human angiostatin and Pgn/plasmin. High levels of Pgn/plasmin were detected in the urine from various cancer patients, whereas healthy individuals sho wed relatively low levels of urine Pgn/plasmin. Of interest, angiostatin is detectable in urine samples of patients with various cancers, including ac ute lymphoblastic leukemia, suggesting that angiogenesis may play an import ant role in the development and progression of leukemia. Our data for the f irst time show that angiostatin and Pgn/plasmin are present at relatively h igh levels in the urine of human cancer patients. Detection of urine angios tatin in cancer patients helps us not only to understand the role of this a ngiogenesis inhibitor in cancer development and progression but also allows us to develop tools of cancer diagnosis and prognosis. Thus angiostatin ha s both therapeutic and diagnostic implications in cancer disease.